Zacks: Brokerages Anticipate Teva Pharmaceutical Industries Limited (TEVA) to Post $0.80 Earnings Per Share
Brokerages forecast that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will announce $0.80 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.73 to $1.00. Teva Pharmaceutical Industries reported earnings of $1.38 per share in the same quarter last year, which suggests a negative year over year growth rate of 42%. The firm is scheduled to announce its next earnings report on Monday, February 12th.
On average, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $3.84 per share for the current financial year, with EPS estimates ranging from $3.78 to $3.88. For the next year, analysts expect that the business will report earnings of $2.79 per share, with EPS estimates ranging from $2.50 to $3.02. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Teva Pharmaceutical Industries.
A number of brokerages have recently weighed in on TEVA. BTIG Research upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Monday, September 11th. TheStreet lowered Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. Credit Suisse Group restated an “underperform” rating and set a $8.00 price objective (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, November 6th. Goldman Sachs Group restated a “neutral” rating and set a $21.00 price objective (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 31st. Finally, Susquehanna Bancshares lowered their price objective on Teva Pharmaceutical Industries from $20.00 to $14.00 and set a “positive” rating on the stock in a research note on Monday, November 6th. Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $21.65.
Teva Pharmaceutical Industries (NYSE:TEVA) opened at $15.06 on Wednesday. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $38.31. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The company has a market capitalization of $15,500.00, a P/E ratio of 3.52 and a beta of 0.55.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 2.26%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries’s payout ratio is presently -12.27%.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.